Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE) (NCT07212751) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)
Hong Kong22,000 participantsStarted 2020-01-29
Plain-language summary
The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.
Who can participate
Age range
18 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment
* If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.
Exclusion Criteria:
* Patient who did not undergo cardiac CT scan due to inability to undergo cardiac CT scanning, kidney failure (serum creatinine \>250 μmol/L or estimated glomerular filtration rate \<30 mL/min), major allergy to contrast.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is no longer recruiting new patients — does that mean there's any chance I could still be considered for enrollment, or is that window completely closed?
2The trial is measuring things like nonfatal stroke, heart attack, and cardiovascular death as its main outcomes — what does that tell us about where I personally stand in terms of those risks, and how does that fit into my current situation?
3The study focuses on using CT coronary angiography to look at plaque features like calcified and non-calcified plaque, as well as FFR-CT — is this type of imaging something that would be relevant or useful for my own care right now, outside of this trial?
4Since this trial is listed as phase 'NA,' meaning it's more of an observational or diagnostic study rather than a drug or device trial, does that change the kind of risks or benefits I should be thinking about compared to a traditional treatment trial?
5Are there standard-of-care approaches to evaluating coronary plaque and guiding my treatment that my care team is already using, and how does the approach being studied in CT-PLAQUE compare to what I'd receive outside of a trial?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death